Literature DB >> 12591722

Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells.

Xinqiao Zhang1, Asha S Multani, Jain-Hua Zhou, Jerry W Shay, David McConkey, Li Dong, Chang-Soo Kim, Charles J Rosser, Sen Pathak, William F Benedict.   

Abstract

Retinoblastoma (RB)94, which lacks the NH(2)-terminal 112 amino acid residues of the full-length RB protein (RB110), is a more potent tumor and growth suppressor than RB110. In this study, Ad-RB94, but not Ad-RB110, produced marked growth inhibition, cytotoxicity, caspase-dependent apoptosis, and G(2)-M block in the human RB-negative, telomerase-positive bladder cancer cell line UM-UC14. This effect was completely inhibited by pretreatment with caspase inhibitors (P < 0.0001). Similar results were seen in RB-positive and other RB-negative bladder cancer cell lines. Ad-RB94 produced rapid telomere length shortening and loss of telomere signal, which was associated with polyploidy and chromosomal aberrations (P < 0.001). Ad-RB94, however, showed no cytotoxicity to telomerase-negative human normal urothelium cells but was highly cytotoxic to telomerase-positive human E6 and E7 immortalized urothelial cells (P < 0.0001). In addition, telomerase-negative cells, which maintain their telomere length through an alternative lengthening of telomeres DNA recombination pathway, showed no cytotoxicity to RB94. These results suggest that the induction of rapid telomere erosion and chromosomal crisis by RB94 in telomerase-positive cancer and in telomerase-expressing immortalized human cells is a major factor in its selective and potent tumor suppression and cytotoxic activity. The lack of cytotoxicity to normal cells should also provide a high therapeutic index when used in gene therapy protocols for the treatment of bladder and other cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591722

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.

Authors:  Ana Aparicio; Robert B Den; Karen E Knudsen
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

2.  A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers.

Authors:  Arlene Siefker-Radtke; Xin-Qiao Zhang; Charles C Guo; Yu Shen; Kathleen F Pirollo; Sharjeel Sabir; Chris Leung; Cindy Leong-Wu; Chi-Ming Ling; Esther H Chang; Randall E Millikan; William F Benedict
Journal:  Mol Ther       Date:  2016-06-13       Impact factor: 11.454

3.  Targeting the RB-pathway in cancer therapy.

Authors:  Erik S Knudsen; Jean Y J Wang
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo.

Authors:  Kathleen F Pirollo; Antonina Rait; Qi Zhou; Xin-qiao Zhang; Jain Zhou; Chang-Soo Kim; William F Benedict; Esther H Chang
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

5.  Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation.

Authors:  J Zhou; X-Q Zhang; F Ashoori; D J McConkey; M A Knowles; L Dong; W F Benedict
Journal:  Cancer Gene Ther       Date:  2008-07-25       Impact factor: 5.987

6.  BRCA1 inhibition of telomerase activity in cultured cells.

Authors:  Jingbo Xiong; Saijun Fan; Qinghui Meng; Laura Schramm; Chenguang Wang; Boumedienne Bouzahza; Jinnian Zhou; Brian Zafonte; Itzhak D Goldberg; Bassem R Haddad; Richard G Pestell; Eliot M Rosen
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

7.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

Review 8.  Biology of urothelial tumorigenesis: insights from genetically engineered mice.

Authors:  Xue-Ru Wu
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

9.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

Review 10.  p53 and retinoblastoma pathways in bladder cancer.

Authors:  Anirban P Mitra; Marc Birkhahn; Richard J Cote
Journal:  World J Urol       Date:  2007-08-21       Impact factor: 3.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.